Charité - Universitätsmedizin Berlin
Berlin, 10117, Germany
Location status: Recruiting
Location contact
Margitta Worm, Prof.
CONTACT
Philipp Globig, Dr.
CONTACT
NCT Number: NCT05334940
The Atopy Registry aims to assess data about atopic disorders and their medical care in a standardized form. With this, the comparative efficacy, tolerability and safety of systemic therapies for atopic disorders should be investigated. An optional additional module "Bioanalytic" shall provide insights into further connections regarding immunology, genetics and microbiome.
Interested in participating?
Request Info6 year and older
All sexes
Observational
Berlin, 10117, Germany
Location status: Recruiting
Margitta Worm, Prof.
CONTACT
Philipp Globig, Dr.
CONTACT
The prevalence of atopic disorders increased in the western countries within the past decades. Atopic disorders are among others: food allergy, atopic dermatitis, allergic rhinitis, bronchial asthma, chronic spontaneous urticaria, eosinophilic esophagitis and chronic rhinosinusitis with nasal polyposis.
Seriously affected patients often have coexisting atopic disorders. In fact, 60-75% of the patients with a severe atopic dermatitis also suffer from an allergic rhinoconjunctivitis and 40-50% from bronchial asthma. This leads to a decreased quality of life (LG) especially in seriously affected patients.
The treatment of atopic disorders is not standardized yet. The Atopy Registry should promote the creation of a Germany-wide registry for different atopic disorders.Furthermore, the registry should characterize the medical care of patients with atopic disorders (patient satisfaction, therapy order, treatment success). This study serves as a longterm observation und is designed to compare different systemic therapies, since head-to-head studies regarding the efficacy are still missing. The analysis of biomaterial is involved to state possible correlations between endotype and phenotype.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients do not receive intervention
Time frame: 3 years
Improvement of at least one comorbidity with biologics therapy using a standardized questionnaire to assess disease severity for the following atopic diseases:
Food Allergy: Food Allergy Quality of Life Questionnaire (FAQLQ) (type-dependent 23-30 items, score between 0 and 6; mean of scores, minimum = 0, maximum = 6; higher score = higher impact on quality of life)
Time frame: 3 years
Improvement of at least one comorbidity with biologics therapy using a standardized questionnaire to assess disease severity for the following atopic diseases:
Atopic Dermatitis: Atopic Dermatitis-Control-Test (ADCT) (6 items, score between 0 and 4; sum, minimum = 0, maximum = 24; higher score = higher severity)
Time frame: 3 years
Improvement of at least one comorbidity with biologics therapy using a standardized questionnaire to assess disease severity for the following atopic diseases:
Bronchial Asthma: Asthma-Control-Test (ACT) (5 items, score between 0 and 5; sum, minimum = 0, maximum = 25; higher score = better disease control)
Time frame: 3 years
Improvement of at least one comorbidity with biologics therapy using a standardized questionnaire to assess disease severity for the following atopic diseases:
Chronic rhinosinusitis with nasal polyps: 22 Items Sino-Nasal Outcome Test (SNOT22) (22 items, score between 0 and 5; sum, minimum = 0, maximum = 110; higher score = higher impact on quality of life)
Time frame: 3 years
Improvement of at least one comorbidity with biologics therapy using a standardized questionnaire to assess disease severity for the following atopic diseases:
Chronic Spointaneous Urticaria: Urticaria Control Test (UCT) (4 items, score between 0 and 5; sum, minimum = 0, maximum = 20; higher score = better control)
Time frame: 3 years
Improvement of at least one comorbidity with biologics therapy using a standardized questionnaire to assess disease severity for the following atopic diseases:
Eosinophilic Esophagitis: Dysphagia Symptoms Questionnaire (DSQ) (4 items, score between 0 and 4 but question-dependent; sum, minimum = 0, maximum = 10; higher score = higher impact)
Time frame: 3 years
Improvement of at least one comorbidity with biologics therapy using a standardized questionnaire to assess disease severity for the following atopic diseases:
Allergic Rhinitis: Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) (28 items, score between 0 and 6; mean, minimum = 0, maximum = 6; higher score = higher impact on quality of life)
Time frame: 3 years
Altered assessment of severity by investigation of oral thresholds and accidental reactions by oral food challenge.
Time frame: 3 years
Altered assessment of severity and/or LQ using the Eczema Area and Severity Index (EASI).
(Eczema Area and Severity; minimum = 0, maximum = 72; higher numbers = higher severity)
Time frame: 3 years
Altered assessment of severity using the Total Nasal Symptom Score (TNSS). (Total Nasal Symptom Score; 3 items, score between 0 and 3; minimum = 0, maximum = 9; higher score = higher severity)
Time frame: 3 years
Altered assessment of severity using the lung function parameter Forced Vital Capacity (FVC)
Time frame: 3 years
Altered assessment of severity using the lung function parameter Forced Expiratory Volume in 1 second (FEV1)
Time frame: 3 years
Altered assessment of severity using the lung function parameter Forced expiratory flow 25-75 (FEF25-75).
Time frame: 3 years
Altered assessment of LQ using the Chronic Urticaria Questionnaire for Quality of Life (CUQ2oL).
(Chronic Urticaria Questionnaire for Quality of Life; 23 items, score between 0 and 4; the score is calculated in percentage, minimum = 0%, maximum = 100%; higher percentage = lower quality of life)
Time frame: 3 years
Altered assessment of severity using the Angioedema Control Test (AECT). (Angioedema Control Test; 4 items, score between 0 and 4; minimum = 0, maximum = 16; lower score = higher severity)
Time frame: 3 years
Altered assessment of severity and/or LQ using the 7-Days Urticaria Activity Score (UAS7).
(7-Days Urticaria Activity Score; 2 items on 7 days, score between 0 and 3; minimum = 0, maximum = 42; higher score = higher severity)
Time frame: 3 years
Altered assessment of LQ using the Pediatric Quality of Life Inventory Eosinophilic Esophagitis (PedsQLEoE).
(Pediatric Quality of Life Inventory Eosinophilic Esophagitis; 33 items, score between 0 and 4; scores are graded on an 0-100 scale in opposite order (0=100, 1=75, 2=50, 3=25, 4=0); minimum = 0, maximum = 100; higher mean score = higher quality of life
Time frame: 3 years
Altered assessment of severity using the Nasal Polyp Score. (Nasal Polyp Score; 2 items, score between 0 and 4; minimum = 0, maximum = 8; higher score = higher severity)
Contact information is provided by the study sponsor or research team.
Margitta Worm, Prof.
CONTACT
Philipp Globig, Dr.
CONTACT
Charite University, Berlin, Germany
Other
Acronym: ATAC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03409367
Atopic Dermatitis, Atopic Disorders
Denver, Colorado, United States
View Trial DetailsNCT04397081
Asthma, Atopic Asthma
Adana, Merkez, Turkey (Türkiye)
View Trial DetailsNCT03997175
Atopic Disorders, Immune System Diseases
Lahti, Kanta-Häme, Finland
View Trial DetailsNCT03050151
Atopic Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Birmingham, Alabama, United States
View Trial Details